The National Security Commission on Emerging Biotechnology visited Arzeda in Seattle. The panel discussion focused on domestic biomanufacturing and the importance of stronger U.S. infrastructure to keep advanced biotechnology production from moving overseas.
Read MoreMANE acquires exclusive global licence agreement to produce and commercialize Arzeda's breakthrough Reb M technology, creating a fully integrated value chain for next-generation sugar reduction solutions.
Read MoreArzeda and KENT Specialty Milling, a division of KENT WORLDWIDE™, announce a product development agreement combining Arzeda's Intelligent Protein Design Technology™ with KENT's manufacturing scale and market expertise to advance customer-focused protein solutions.
Read MoreSynBioBeta covers Arzeda's partnership with MANE to commercialize ViaLeaf™ Reb M — a high-purity stevia sweetener with cell-free production capacity over 500 metric tons per year, one of the few industrial-scale cell-free biomanufacturing demonstrations in operation today.
Read MoreMANE and Arzeda announce a strategic partnership to commercialize ViaLeaf™ Reb M, pairing Arzeda's Intelligent Protein Design Technology™ with MANE's global flavor expertise to deliver natural, clean-label sugar reduction without compromising taste or cost.
Read MoreArzeda will lead a $7.8M NSF CFIRE consortium with Missouri S&T and Novonesis to develop AI-designed enzyme cascades powered directly by electricity, targeting >70% energy efficiency and CO₂-to-methanol conversion for sustainable chemical production.
Read MoreArzeda has been selected to lead a ~$6.3M NSF USPRD consortium with Stanford, UNC Chapel Hill, UC Irvine, and UC Davis to scale industrial cell-free biomanufacturing through AI-designed enzymes that operate on cost-effective non-natural cofactors.
Read MoreArzeda doubles ProSweet Reb M™ stevia capacity to 500 metric tons per year — now producing on two continents — just four months after its March 2025 expansion announcement, ensuring reliable supply for North American food and beverage customers.
Read MoreArzeda expands ProSweet Reb M™ stevia production into Europe, lifting capacity past 250 metric tons per year — enough to replace roughly 75,000 tons of sugar — to meet growing demand from CPG companies for a great-tasting, lower-cost natural sweetener.
Read MoreArzeda has been selected for an award from DARPA's Biological Technologies Office under its AI BTO initiative, funding work to design and validate proteins from limited training data — advancing AI-driven protein engineering for national-security applications.
Read MoreArzeda surpasses 10 tons of ProSweet RebM™ stevia production — enough to replace 3,000 tons of sugar — and now employs more than 70 team members across ML, protein testing, strain design, and operations, weeks after co-founder David Baker won the 2024 Nobel Prize in Chemistry.
Read MoreArzeda closes a $38M oversubscribed funding round with new investors Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and W. L. Gore's venture arm to expand ProSweet stevia production and accelerate commercialization of additional designer proteins.
Read MoreArzeda enters a joint development agreement with W. L. Gore & Associates — building on a successful 2022 collaboration — to apply Intelligent Protein Design Technology™ to advance innovation in materials science with improved sustainability and performance benefits.
Read MoreUnilever and Arzeda developed new low-temperature stain-fighting enzymes in just 18 months — five times faster than previous enzyme development — that could halve the number of ingredients needed to deliver effective cleaning and further reduce the carbon footprint of Unilever's Home Care products.
Read MoreArzeda announces a collaboration with Takeda to apply its AI-driven Intelligent Protein Design Technology™ to optimizing therapeutic proteins in Takeda's biologics research pipeline.
Read MoreArzeda launches its ProSweet Enzymes™ portfolio, letting sweetener companies efficiently and cost-effectively produce Reb D and Reb M with consistent purity directly from stevia leaf extract — broadening the reach of Arzeda's enzymatic stevia solutions.
Read MoreArzeda is featured in Nature Biotechnology's coverage of AI-enhanced protein design and how computational tools now make proteins that have never existed in nature.
Read MoreArzeda and AAK enter a joint development agreement to apply Arzeda's protein design platform to enhance the sustainability and production efficiency of AAK's specialty oils and fats for the food industry.
Read MoreArzeda announces a research collaboration with W. L. Gore & Associates to investigate the role computationally designed proteins can play in delivering new classes of materials with superior performance and sustainability attributes.
Read MoreArzeda expands its commercial leadership with Ken Barrett joining as Chief Business Officer and Scott Fabro as Senior Vice President of Food Ingredients, bringing decades of enzyme commercialization experience to drive product revenue.
Read MoreArzeda closes a $33M Series B led by Conti Ventures, with Lewis & Clark Agrifood, Bunge Ventures, Circulate Capital, and repeat Series A investors OS Fund, Casdin Capital, UMI, and Bioeconomy Capital, to accelerate enzyme commercialization across food, home care, and chemicals.
Read MoreUnilever and Arzeda kick off a three-year strategic partnership to apply computational and AI-driven enzyme design across Unilever's cleaning and laundry brands — supporting Unilever's Clean Future commitment to remove virgin fossil-fuel feedstocks from its formulations.
Read MoreCodexis and existing Series A investor Casdin Capital co-invest in Arzeda as part of the SynBio Innovation Accelerator, alongside plans for Codexis and Arzeda to collaborate on areas of synergy and mutual advantage.
Read MoreBiotechnology veteran Doug Cameron, PhD, joins Arzeda's board of directors as the company expands its protein design platform into sustainable food and nutrition ingredients — including natural sweeteners, soluble fibers, structured lipids, plant-based proteins, and cannabinoids.
Read MoreArzeda and Amyris sign a development collaboration agreement — their second joint project — to design novel enzymes for Amyris fermentation processes producing high-value ingredients, with milestone-based funding and a commercialization value share.
Read MoreBP and Arzeda extend their joint development agreement into a second phase, advancing toward commercialization of a renewable chemical of strategic interest to BP and validating the performance of Arzeda's Archytas™ protein design technology.
Read MoreArzeda is featured by GeekWire in "Inside Arzeda's synthetic biology lab, where industrial ingredients are brewed like beer."
Read MoreArzeda is featured in The Economist's April 2019 Technology Quarterly on synthetic biology, examining how the engineering of living organisms could soon start changing many industries.
Read MoreArzeda climbs to #5 in Biofuels Digest's annual "40 Hottest Technologies in the Advanced Bioeconomy" list — up from #6 in 2017 — recognising momentum across the BP partnership, DNA-assembly collaborations, and a DOE bioproduct award.
Read MoreArzeda and BP announce a joint development agreement to design novel enzymes — using Arzeda's Archytas™ industrial protein design software — that enable BP's proprietary pathways for producing a renewable chemical with broad applications.
Read MoreArzeda licenses TeselaGen's cloud-based DNA design platform and partners to extend its biological design automation tools, accelerating Arzeda's design-build-test cycle for computationally designed enzymes and metabolic pathways.
Read MoreArzeda raises $12M in a Series A led by OS Fund, with Bioeconomy Capital, Sustainable Conversion Ventures, and existing seed investor WRF Capital, to scale up its computational protein design platform and expand its product development pipeline.
Read MoreArzeda signs a supply agreement with Gen9 — through Gen9's Multiplex Access Partnership program — for megabase quantities of synthetic DNA to accelerate development of novel enzymes, specialty chemicals, crop traits, and pharmaceutical building blocks.
Read MoreArzeda and Zymergen sign a multi-year agreement combining Arzeda's Archytas™ and Scylax™ enzyme- and pathway-design tools with Zymergen's high-throughput strain construction platform to develop novel molecules and materials.
Read MoreArzeda enters an agreement with Stratos Genomics to design enhanced enzymes for Stratos's single-molecule "Sequencing by Expansion" (SBX) DNA-sequencing platform, applying its industrial protein design software to a critical SBX catalyst.
Read More